We are live on
!
Find out more
SEC
Seven Eight Capital Portfolio holdings
AUM
$1.11B
1-Year Est. Return
29.48%
This Fund
S&P 500
This Quarter
Est. Return
+5.45%
1 Year Est. Return
+29.48%
3 Year Est. Return
+13.61%
5 Year Est. Return
+117.69%
10 Year Est. Return
+239.1%
AUM
$819M
AUM Growth
+$123M
(+18%)
Cap. Flow
+$101M
Cap. Flow
% of AUM
12.29%
Top 10 Holdings %
Top 10 Hldgs %
9.75%
Holding
710
New
168
Increased
162
Reduced
95
Closed
285
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$9.74M |
| 2 |
McDonald's
MCD
|
+$8.2M |
| 3 |
PARA
Paramount Global Class B
PARA
|
+$8.03M |
| 4 |
AGN
Allergan plc
AGN
|
+$7.37M |
| 5 |
Henry Schein
HSIC
|
+$6.53M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nike
NKE
|
+$7.17M |
| 2 |
Lam Research
LRCX
|
+$6.99M |
| 3 |
Electronic Arts
EA
|
+$6.98M |
| 4 |
MBLY
Mobileye N.V.
MBLY
|
+$6.79M |
| 5 |
Hilton Worldwide
HLT
|
+$6.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 15.19% |
| 2 | Technology | 15.05% |
| 3 | Consumer Discretionary | 14.44% |
| 4 | Financials | 11.43% |
| 5 | Consumer Staples | 9.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
376
TJX Companies
TJX
$178B
| $324K | 0.04% |
8,800
-58,000
| -87% | -$2.07M |
|
|
CHL
377
DELISTED
China Mobile Limited
CHL
| $317K | 0.04% |
+6,276
| New | +$334K |
|
378
ATI
ATI
$25.5B
| $315K | 0.04% |
13,159
-29,646
| -69% | -$586K |
|
379
MarketAxess Holdings
MKTX
$4.34B
| $314K | 0.04% |
+1,700
| New | +$325K |
|
380
Charles River Laboratories
CRL
$11.6B
| $313K | 0.04% |
2,900
-2,600
| -47% | -$267K |
|
381
Ingersoll Rand
IR
$33.9B
| $311K | 0.04% |
+11,300
| New | +$266K |
|
|
UCTT
382
Ultra Clean Holdings
UCTT
$3.47B
| $309K | 0.04% |
+10,100
| New | +$239K |
|
|
TFCF
383
DELISTED
Twenty-First Century Fox, Inc. Class B
TFCF
| $304K | 0.04% |
+11,799
| New | +$320K |
|
384
MKS Inc
MKSI
$19.3B
| $302K | 0.04% |
3,200
-30,100
| -90% | -$2.46M |
|
385
Travelers Companies
TRV
$82.9B
| $301K | 0.04% |
2,458
-4,300
| -64% | -$537K |
|
386
Entegris
ENTG
$18B
| $297K | 0.04% |
10,300
+3,500
| +51% | +$89K |
|
|
PTHN
387
DELISTED
Patheon N.V.
PTHN
| $290K | 0.04% |
8,288
+4,388
| +113% | +$153K |
|
388
KBR
KBR
$4.74B
| $284K | 0.03% |
+15,900
| New | +$257K |
|
389
Portland General Electric
POR
$5.92B
| $283K | 0.03% |
+6,200
| New | +$286K |
|
390
Booz Allen Hamilton
BAH
$8.8B
| $277K | 0.03% |
+7,400
| New | +$254K |
|
391
Zoetis
ZTS
$32.5B
| $273K | 0.03% |
4,279
-64,800
| -94% | -$4.06M |
|
392
Ashland
ASH
$3.11B
| $269K | 0.03% |
4,119
-2,900
| -41% | -$185K |
|
|
NUAN
393
DELISTED
Nuance Communications, Inc.
NUAN
| $267K | 0.03% |
19,635
-46,085
| -70% | -$658K |
|
394
Ziff Davis
ZD
$1.95B
| $266K | 0.03% |
+4,140
| New | +$280K |
|
395
Thermo Fisher Scientific
TMO
$214B
| $265K | 0.03% |
+1,400
| New | +$254K |
|
396
Cracker Barrel
CBRL
$1.2B
| $262K | 0.03% |
1,727
+1,284
| +290% | +$196K |
|
397
Sempra
SRE
$59.2B
| $262K | 0.03% |
4,600
-1,400
| -23% | -$81K |
|
398
BioMarin Pharmaceuticals
BMRN
$12B
| $261K | 0.03% |
2,800
-32,800
| -92% | -$2.9M |
|
399
Ameren
AEE
$31.1B
| $260K | 0.03% |
4,500
-4,900
| -52% | -$283K |
|
|
IBKC
400
DELISTED
IBERIABANK Corp
IBKC
| $255K | 0.03% |
3,100
+2,200
| +244% | +$173K |
|
Similar funds
PP
ECM
GCAC
CAM
D
GFS
FTIS
AIA
Seven Eight Capital's Q3 2017 Portfolio in Review
As of Q3 2017, Seven Eight Capital held 710 positions worth $819M, up 18% from $696M the previous quarter. Its ten largest holdings account for 9.8% of the portfolio.
Seven Eight Capital deployed $101M of net new capital in Q3 2017, opening 168 new positions and adding to 162 existing holdings. Its largest new stake was Intercept Pharmaceuticals, Inc.: 90,387 shares worth $5.25M.
By sector, the portfolio is most concentrated in Healthcare at 15% of assets, up from 10% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Constellation Brands, an estimated $6.37M trimmed.
- Seven Eight Capital's largest Q3 2017 buy was Intercept Pharmaceuticals, Inc.: 90,387 shares worth $5.25M.
- Seven Eight Capital added most to McDonald's in Q3 2017, an estimated $8.2M increase.
- Seven Eight Capital's biggest Q3 2017 reduction was Constellation Brands, cutting an estimated $6.37M.
- Seven Eight Capital fully exited Nike in Q3 2017, selling an estimated $7.17M.
- Seven Eight Capital's ten largest holdings make up 9.8% of its $819M portfolio in Q3 2017.
- Seven Eight Capital opened 168 new positions and closed 285 in Q3 2017.
- Seven Eight Capital's portfolio value rose 18% quarter-over-quarter to $819M.
Based on Seven Eight Capital's 13F filing for Q3 2017, filed 16 Oct 2017.